CDP-CHOLINE A HOST-DIRECTED THERAPEUTIC FOR DISEASE CAUSED BY SARS COV-2 INFECTION

Abstract: compositions and methods are disclosed for treating coronavirus infections, such as sars cov-2 coronavirus infections. for example, a composition is disclosed that contains one, two, or more cytidine diphosphate (cdp)-conjugated phospholipid precursors selected from the group consisting of cdp-choline (cdp-cho), cdp-ethanolamine (cdp-eth), and cdpdiacylglycerol (cdp-dag) in combination with one or more agents for treating covid-19, such as corticosteroids, antibodies, or antivirals, in a pharmaceutically acceptable carrier. also disclosed is a method of treating coronavirus (e.g. sars cov-2) infection in a subject that involves administering to the subject one, two, or more cytidine diphosphate (cdp)-conjugated phospholipid precursors selected from the group consisting of cdp-choline (cdp-cho), cdpethanolamine (cdp-eth), and cdp-diacylglycerol (cdp-dag) in combination with agents for treating covid-19, such as corticosteroids, antibodies, or antivirals.

Inventor(s): Ian Christopher Davis, Jean E. Schelhorn

CPC Classification: A61K47/549 ({Sugars, nucleosides, nucleotides or nucleic acids})

Search for rejections for patent application number 20250170246